Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS
Sign Up to like & getrecommendations! Published in 2019 at "Cardiovascular Diabetology"
DOI: 10.1186/s12933-019-0921-2
Abstract: BackgroundTo examine the effects of the DPP-4i sitagliptin on CV outcomes during and after incident MI in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).MethodsTECOS randomized 14,671 participants with type 2 diabetes and atherosclerotic cardiovascular… read more here.
Keywords: sitagliptin; hospitalization heart; group; heart failure ... See more keywords
In HFpEF, the benefit of empagliflozin on a composite of CV death or HF hospitalization at 26 mo did not vary by diabetes status
Sign Up to like & getrecommendations! Published in 2022 at "Annals of Internal Medicine"
DOI: 10.7326/j22-0075
Abstract: SOURCE CITATION Filippatos G, Butler J, Farmakis D, et al. Empagliflozin for heart failure with preserved left ventricular ejection fraction with and without diabetes. Circulation. 2022;146:676-86. 35762322. read more here.
Keywords: benefit empagliflozin; hospitalization vary; hfpef benefit; death hospitalization ... See more keywords